Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Dabomb Protein Biotech's Enterprise Value is NT$1,158.2 Mil.
Dabomb Protein Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-21.0 Mil. Therefore, Dabomb Protein Biotech's EV-to-FCF for today is -55.04.
The historical rank and industry rank for Dabomb Protein Biotech's EV-to-FCF or its related term are showing as below:
ROCO:6578'
s EV-to-FCF Range Over the Past 10 Years
Min: -2136.3 Med: -6.26 Max: 1568.37
Current: -51.96
During the past 13 years, the highest EV-to-FCF of Dabomb Protein Biotech was 1568.37. The lowest was -2136.30. And the median was -6.26.
ROCO:6578's EV-to-FCF is ranked worse than 100% of 1190
companies
in the Consumer Packaged Goods industry
Industry Median: 15.92
vs ROCO:6578: -51.96
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dabomb Protein Biotech (ROCO:6578) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dabomb Protein Biotech's PE Ratio (TTM) for today is calculated as:
Dabomb Protein Biotech's share price for today is NT$17.30.
Dabomb Protein Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.960.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Dabomb Protein Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dabomb Protein Biotech EV-to-FCF vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Dabomb Protein Biotech's EV-to-FCF falls into.
Dabomb Protein Biotech's current Enterprise Value is NT$1,158.2 Mil.
Dabomb Protein Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-21.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dabomb Protein Biotech (ROCO:6578) has a EV-to-FCF of -55.04 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Dabomb Protein Biotech and its competitors. According to the industry distribution chart, Dabomb Protein Biotech ranks #999999 out of 1190 companies in the Consumer Packaged Goods industry.
Is Dabomb Protein Biotech's EV-to-FCF too high?
Dabomb Protein Biotech's current EV-to-FCF is -55.04. Based on the distribution chart, Dabomb Protein Biotech ranks #999999 out of 1190 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Dabomb Protein Biotech has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's EV-to-FCF compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Dabomb Protein Biotech ranks #999999 out of 1190 companies for EV-to-FCF. This places Dabomb Protein Biotech in the lower half of its industry. The industry median EV-to-FCF is 15.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Consumer Packaged Goods company?
The median EV-to-FCF among Consumer Packaged Goods companies is 15.92, based on 1,190 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Dabomb Protein Biotech and its competitors. For the Consumer Packaged Goods industry, the median EV-to-FCF is 15.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dabomb Protein Biotech's current EV-to-FCF is -55.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$14.48, compared to a current price of NT$17.30 — trading 19.5% above its estimated fair value. The current EV-to-FCF is -55.04. Dabomb Protein Biotech's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current EV-to-FCF is -55.04 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?
Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be overvalued.
The current stock price of NT$17.30 is trading 19.5% above its estimated GF Value™ of NT$14.48.
GuruFocus considers Dabomb Protein Biotech to be Modestly Overvalued.
Key valuation signals for ROCO:6578:
EV-to-FCF: -55.04
GF Value™: NT$14.48 vs. price of NT$17.30 (19.5% above fair value)
No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
59GF Score
Get the complete analysis for ROCO:6578
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6578 has been successfully added to your 
